STUDY SHOWS EYE HEALTH SUPPLEMENT LOWERS INTRAOCULAR PRESSURE AND IMPROVES BLOOD FLOW
Research reveals Mirtogenol^® strengthens effect of medication in lowering elevated intraocular pressure

(May 20, 2010) - HOBOKEN, NJ - Nearly ten percent of U.S. adults suffer from ocular hypertension, a condition that occurs when the amount of oxygen and nutrient-rich fluid circulated through the eye exceeds the amount that is drained. Ocular hypertension may lead to loss of vision and glaucoma. A study published in the May issue of Clinical Ophthalmology reveals Mirtogenol^®, taken with Latanoprost medication, effectively improves blood flow to the eyes in patients with ocular hypertension and aids in further normalizing ocular pressure. 

"Ocular hypertension is not only a major contributor to impaired vision, but can result in serious health challenges including glaucoma, a condition that affects nearly 2.5 million U.S. adults" said Dr. Robert Steigerwalt, Jr., lead researcher of the study. "Consistent with previous studies, this new research further demonstrates that Mirtogenol^® is an effective, natural solution for improving blood flow through the central retinal arteries."

Subjects underwent complete eye exams which found no signs of primary open angle glaucoma or visual field defects. 

Subjects were randomly divided into three groups to receive treatments of prescription eye drop medication Latanoprost, Mirtogenol^® tablets, or a combination of both. Each Mirtogenol^® tablet contains 40mg of Pycnogenol^® and 80mg of Mirtoselect^®. Subjects consumed one Mirtogenol^® tablet once in the morning. Latanoprost was taken as one drop per eye daily in the evening. The patients� intraocular pressure was measured at the same time in the morning at each visit. 

Normal eye pressure ranges from 10-21 mmHg. Ocular hypertension begins at a level greater than 21 mmHg. In the group of subjects taking Mirtogenol^® alone the intraocular pressure was lowered from 38.1 to 29.0 mmHg, whereas in those taking Latanoprost the intraocular pressure decreased from 37.7 to 27.2 mmHg. In the third group of patients who took a combination of Mirtogenol^® and Latanoprost, the intraocular pressure decreased from 38.0 to 23.0 mmHg. The study concluded that the combination of Mirtogenol^® and Latanoprost was more effective than each constituent alone for lowering intraocular pressure, and also yielded better retinal blood flow. 

"Mirtogenol^® is the first dietary supplement clinically proven to improve blood flow in the central retinal artery and hence useful to normalize intraocular pressure," said Dr. Steigerwalt. "Taking Mirtogenol^® in addition to Latanoprost is safe, and patients can expect further improved ocular pressure from this combination."

A previous study in Molecular Vision revealed that Mirtogenol^® lowered high intraocular pressure, which translates into a decreased risk for developing glaucoma later in life. Mirtogenol^® represents the first effective nutritional intervention for supporting a healthier pressure in the eyes. This study addresses the needs of people with diagnosed ocular hypertension who take medications, and now have a nutritional option to further improve their eye health. While several circumstances are believed to be involved in the development of glaucoma, an elevated intraocular pressure is certain to represent the greatest variable risk factor. 

Mirtogenol^® is a safe and efficacious patent-pending formula and is available on an exclusive basis with selected retailers worldwide. For a complete history on this proprietary breakthrough eye health supplement, visit www.mirtogenol.com